Skip to main content
. 2022 Jan 31;12:747482. doi: 10.3389/fonc.2022.747482

Figure 2.

Figure 2

Lirilumab and Avelumab Enhance Anti-Tumor Activity in vivo. (A) Tumor-bearing mice administered IgG (control), aLy49 (20 mg/kg daily), or aLy49 (40 mg/kg daily) intraperitoneally (i.p.) seven days (D7) after HPV+ U14 cervical tumor cell implantation. (B) Tumor-bearing mice administered IgG (control), aPdl1 (2 mg/kg daily), or aPdl1 (4 mg/kg daily) i.p. seven days after HPV+ U14 cell implantation. (C) aLy49 (20 mg/kg daily) plus aPdl1 (2 mg/kg daily) starting on D7. (D) Tumor-bearing mice administered IgG (control) or aLy49 (20 mg/kg daily) plus aPdl1 (2 mg/kg daily) i.p. starting at D14. (E) Tumor-bearing mice were administered IgG (control) or aLy49 (20 mg/kg daily) plus aPdl1 (2 mg/kg daily) i.p. starting at D7 or D14. *P < 0.05, **P < 0.01 versus control group, †P < 0.05, ††P < 0.01 versus aLy49 group, ‡P < 0.05 versus aPdl1 group [(left) one-way ANOVA or (right) log-rank test]. n=12 mice per cohort.